CO7160108A2 - Formulación de implantes de risperidona o paliperidona - Google Patents
Formulación de implantes de risperidona o paliperidonaInfo
- Publication number
- CO7160108A2 CO7160108A2 CO14285844A CO14285844A CO7160108A2 CO 7160108 A2 CO7160108 A2 CO 7160108A2 CO 14285844 A CO14285844 A CO 14285844A CO 14285844 A CO14285844 A CO 14285844A CO 7160108 A2 CO7160108 A2 CO 7160108A2
- Authority
- CO
- Colombia
- Prior art keywords
- risperidone
- composition
- weeks
- drug
- paliperidone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se dirige a una composición de liberación sostenida inyectable por vía intramuscular, adecuada para la formación de un implante sólido ¡n situ en un organismo, que comprende un fármaco que es risperidona y/o paliperidona o cualquier sal farmacéuticamente aceptable de las mismas en cualquier combinación, un copolímero biocompatible a base de ácido láctico y ácido glicólico con una relación monomérica entre el ácido láctico y el ácido glicólico de cerca de 50:50 y DMSO como disolvente, en que la composición libera el fármaco con un comienzo de acción inmediato y de manera continua durante al menos cuatro semanas y en que la composición tiene un perfil farmacocinético ¡n vivo que la hace adecuada para su administración cada cuatro semanas o perlados aún más largos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12170362.3A EP2529756B1 (en) | 2011-05-31 | 2012-05-31 | Risperidone and/or Paliperidone implant formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO7160108A2 true CO7160108A2 (es) | 2015-01-15 |
Family
ID=46147376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO14285844A CO7160108A2 (es) | 2012-05-31 | 2014-12-30 | Formulación de implantes de risperidona o paliperidona |
Country Status (30)
| Country | Link |
|---|---|
| EP (2) | EP2529756B1 (es) |
| JP (1) | JP6367795B2 (es) |
| KR (1) | KR101880716B1 (es) |
| CN (1) | CN104363923A (es) |
| AU (1) | AU2013269547B2 (es) |
| BR (1) | BR112014029209A2 (es) |
| CA (1) | CA2874765C (es) |
| CL (1) | CL2014003216A1 (es) |
| CO (1) | CO7160108A2 (es) |
| CY (1) | CY1124369T1 (es) |
| DK (1) | DK2529756T3 (es) |
| EA (1) | EA031819B1 (es) |
| ES (1) | ES2878112T3 (es) |
| HR (1) | HRP20211057T1 (es) |
| IL (1) | IL235849B (es) |
| IN (1) | IN2014DN10672A (es) |
| LT (1) | LT2529756T (es) |
| MA (1) | MA37664B1 (es) |
| MX (1) | MX2014014483A (es) |
| MY (1) | MY174999A (es) |
| NZ (1) | NZ703321A (es) |
| PH (1) | PH12014502667A1 (es) |
| PL (1) | PL2529756T3 (es) |
| PT (1) | PT2529756T (es) |
| RS (1) | RS62059B1 (es) |
| SG (1) | SG11201407961WA (es) |
| SI (1) | SI2529756T1 (es) |
| UA (1) | UA119430C2 (es) |
| WO (1) | WO2013178812A1 (es) |
| ZA (1) | ZA201409299B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| CN101801415B (zh) | 2007-05-25 | 2015-09-23 | Rb医药品有限公司 | 利培酮化合物的持续递送制剂 |
| US10285936B2 (en) | 2010-05-31 | 2019-05-14 | Laboratorios Farmacéuticos Rovi, S.A. | Injectable composition with aromatase inhibitor |
| US10335366B2 (en) | 2010-05-31 | 2019-07-02 | Laboratorios Farmacéuticos Rovi, S.A. | Risperidone or paliperidone implant formulation |
| EP2394664B1 (en) | 2010-05-31 | 2016-06-01 | Laboratorios Farmaceuticos Rovi, S.A. | Antipsychotic injectable depot composition |
| US10350159B2 (en) | 2010-05-31 | 2019-07-16 | Laboratories Farmacéuticos Rovi, S.A. | Paliperidone implant formulation |
| PL2394663T3 (pl) | 2010-05-31 | 2022-02-21 | Laboratorios Farmaceuticos Rovi, S.A. | Kompozycje do wstrzykiwania implantów biodegradowalnych in-situ |
| US10881605B2 (en) | 2010-05-31 | 2021-01-05 | Laboratorios Farmaceuticos Rovi, S.A. | Methods for the preparation of injectable depot compositions |
| US10463607B2 (en) | 2010-05-31 | 2019-11-05 | Laboratorios Farmaceutics Rofi S.A. | Antipsychotic Injectable Depot Composition |
| DK2529756T3 (da) * | 2011-05-31 | 2021-08-02 | Farm Rovi Lab Sa | Risperidon- og/eller paliperidon-implantatformulering |
| SI2529757T1 (sl) * | 2011-05-31 | 2014-05-30 | Laboratorios Farmaceuticos Rovi, S.A. | Formulacija paliperidon implantata |
| CN109602692B (zh) | 2013-03-11 | 2022-11-04 | 度瑞公司 | 包含高粘度液体载体的可注射控制释放组合物 |
| US20140308352A1 (en) | 2013-03-11 | 2014-10-16 | Zogenix Inc. | Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material |
| CN104922085B (zh) * | 2015-06-01 | 2016-10-26 | 湖南赛沃药业有限公司 | 一种利培酮植入剂及其制备方法 |
| CN109589304A (zh) * | 2017-10-01 | 2019-04-09 | 万特制药(海南)有限公司 | 利培酮口服溶液及其制备方法 |
| MX2020012459A (es) | 2018-05-24 | 2021-04-28 | Celanese Eva Performance Polymers Llc | Dispositivo implantable para liberacion sostenida de un compuesto de farmaco macromolecular. |
| JP2021524841A (ja) | 2018-05-24 | 2021-09-16 | セラニーズ・イーブイエイ・パフォーマンス・ポリマーズ・エルエルシー | 高分子薬剤化合物の持続放出用の埋め込み型デバイス |
| TW202313047A (zh) | 2021-09-21 | 2023-04-01 | 西班牙商禾霏藥品實驗室有限公司 | 抗精神病可注射儲積型組合物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3645906B2 (ja) | 1993-11-19 | 2005-05-11 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | マイクロカプセル封入された３−ピペリジニル−置換１，２−ベンズイソオキサゾール類及び１，２−ベンズイソチアゾール類 |
| WO2004064752A2 (en) * | 2003-01-22 | 2004-08-05 | Alkermes Controlled Therapeutics, Inc. | Method of preparing sustained release microparticles |
| CA2819769C (en) * | 2003-07-18 | 2016-06-28 | Oakwood Laboratories, L.L.C. | Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions |
| EP1802286B1 (en) | 2004-08-04 | 2008-07-23 | ALZA Corporation | Sustained drug release composition demonstrating an ascending zero order release pattern, methods of manufacturing such a composition |
| BRPI0809837A2 (pt) | 2007-04-19 | 2014-11-11 | Youxin Li | "composto para tratamento de distúrbios mentais, saldo do composto para tratamento de distúrbios mentais, composição farmacéutica e uso do composto para tratamento de distúrbios mentais" |
| EP3115038A1 (en) * | 2007-05-18 | 2017-01-11 | DURECT Corporation | Improved depot formulations |
| CN101801415B (zh) * | 2007-05-25 | 2015-09-23 | Rb医药品有限公司 | 利培酮化合物的持续递送制剂 |
| WO2009015828A1 (en) | 2007-07-27 | 2009-02-05 | Synthon B.V. | Paliperidone derivatives |
| US9439906B2 (en) | 2007-12-19 | 2016-09-13 | Janssen Pharmaceutica Nv | Dosing regimen associated with long acting injectable paliperidone esters |
| US8758780B2 (en) | 2009-10-06 | 2014-06-24 | Ascendis Pharma As | Subcutaneous paliperidone composition |
| EP2394664B1 (en) * | 2010-05-31 | 2016-06-01 | Laboratorios Farmaceuticos Rovi, S.A. | Antipsychotic injectable depot composition |
| PL2394663T3 (pl) * | 2010-05-31 | 2022-02-21 | Laboratorios Farmaceuticos Rovi, S.A. | Kompozycje do wstrzykiwania implantów biodegradowalnych in-situ |
| DK2529756T3 (da) * | 2011-05-31 | 2021-08-02 | Farm Rovi Lab Sa | Risperidon- og/eller paliperidon-implantatformulering |
| SI2529757T1 (sl) * | 2011-05-31 | 2014-05-30 | Laboratorios Farmaceuticos Rovi, S.A. | Formulacija paliperidon implantata |
-
2012
- 2012-05-31 DK DK12170362.3T patent/DK2529756T3/da active
- 2012-05-31 SI SI201231933T patent/SI2529756T1/sl unknown
- 2012-05-31 RS RS20210834A patent/RS62059B1/sr unknown
- 2012-05-31 LT LTEP12170362.3T patent/LT2529756T/lt unknown
- 2012-05-31 PL PL12170362T patent/PL2529756T3/pl unknown
- 2012-05-31 ES ES12170362T patent/ES2878112T3/es active Active
- 2012-05-31 PT PT121703623T patent/PT2529756T/pt unknown
- 2012-05-31 EP EP12170362.3A patent/EP2529756B1/en active Active
-
2013
- 2013-05-31 EA EA201401346A patent/EA031819B1/ru unknown
- 2013-05-31 AU AU2013269547A patent/AU2013269547B2/en active Active
- 2013-05-31 KR KR1020147035300A patent/KR101880716B1/ko active IP Right Grant
- 2013-05-31 BR BR112014029209A patent/BR112014029209A2/pt not_active Application Discontinuation
- 2013-05-31 MY MYPI2014703551A patent/MY174999A/en unknown
- 2013-05-31 CN CN201380027927.8A patent/CN104363923A/zh active Pending
- 2013-05-31 MX MX2014014483A patent/MX2014014483A/es active IP Right Grant
- 2013-05-31 UA UAA201414187A patent/UA119430C2/uk unknown
- 2013-05-31 EP EP13726003.0A patent/EP2854858A1/en active Pending
- 2013-05-31 CA CA2874765A patent/CA2874765C/en active Active
- 2013-05-31 SG SG11201407961WA patent/SG11201407961WA/en unknown
- 2013-05-31 WO PCT/EP2013/061320 patent/WO2013178812A1/en active Application Filing
- 2013-05-31 IN IN10672DEN2014 patent/IN2014DN10672A/en unknown
- 2013-05-31 JP JP2015514533A patent/JP6367795B2/ja active Active
- 2013-05-31 NZ NZ703321A patent/NZ703321A/en unknown
-
2014
- 2014-11-23 IL IL235849A patent/IL235849B/en active IP Right Grant
- 2014-11-26 CL CL2014003216A patent/CL2014003216A1/es unknown
- 2014-11-28 PH PH12014502667A patent/PH12014502667A1/en unknown
- 2014-12-16 MA MA37664A patent/MA37664B1/fr unknown
- 2014-12-17 ZA ZA2014/09299A patent/ZA201409299B/en unknown
- 2014-12-30 CO CO14285844A patent/CO7160108A2/es unknown
-
2021
- 2021-07-02 HR HRP20211057TT patent/HRP20211057T1/hr unknown
- 2021-07-16 CY CY20211100644T patent/CY1124369T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO7160108A2 (es) | Formulación de implantes de risperidona o paliperidona | |
| CO7160109A2 (es) | Formulación de implantes de paliperidona | |
| EA201890852A1 (ru) | Соли валбеназина и их полиморфы | |
| UY32874A (es) | Compuestos y composiciones como moduladores de la actividad de tlr | |
| WO2016042163A3 (en) | Ophthalmic drug compositions | |
| ECSP12012326A (es) | Derivados de aminopirimidina como moduladores de la lrrk2 | |
| CY1122793T1 (el) | Χλωριουχο αλας του tat-nr2b9c | |
| NI201000193A (es) | Formulaciones orales de análogos de citidina y métodos de uso de las mismas. | |
| BRPI1002601E2 (pt) | composição nanoestruturada de uso veterinário para administração de fármacos | |
| WO2014134586A3 (en) | Injectable long-acting local anesthetic semi-solid formulations and its compostions | |
| CL2017000664A1 (es) | Micropartículas inyectables para la liberación hiper-localizada de agentes terapéuticos | |
| CO2017003305A2 (es) | Derivados de la amida del ácido 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carboxílico o del 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carbonitrilo como inhibidores de aldosterona sintasa | |
| ECSP14013156A (es) | Tetrahidroquinolinas condensadas con cicloalquilo como moduladores de receptores de crth2. | |
| AR096854A1 (es) | Composición farmacéutica para una liberación sostenida de lanreotide | |
| NZ738463A (en) | Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester | |
| BR112014009242A2 (pt) | nanossuspensão farmacêutica | |
| EA201291104A1 (ru) | Пероральные лекарственные формы бендамустина | |
| AR098024A1 (es) | Fármaco para la prevención y/o tratamiento de la poliquistosis renal | |
| WO2014119985A3 (es) | Composición farmacéutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral | |
| CO6551752A2 (es) | Formulaicòn de liberaciòn sostenida | |
| UY37798A (es) | Composiciones sólidas orales de betahistina de liberación prolongada no pulsátil | |
| NI201400136A (es) | Compuestos d - aminoácidos para enfermedad hepática |